← Back
Data updated: Jun 28, 2026
THE FEINSTEIN INST
Generics Pharmaceuticals
THE FEINSTEIN INST is a generic drug manufacturer with 1 FDA-approved products.
2014
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Upcoming FDA Decisions
Full Calendar → Jul 11, 2026 — Relacorilant + nab-paclitaxel
0d Jul 23, 2026 — Rivoceranib + camrelizumab
Jul 23, 2026 — Rivoceranib + camrelizumab
THE FEINSTEIN INST's Key Drugs
THE FEINSTEIN INST's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
THE FEINSTEIN INST's Recent FDA Approvals
New NDA/BLA approvals for THE FEINSTEIN INST over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
THE FEINSTEIN INST's Therapeutic Areas
Disease areas where THE FEINSTEIN INST has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
THE FEINSTEIN INST Pipeline Snapshot
Active clinical trials for THE FEINSTEIN INST across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2014-11-19
- Latest
- 2014-11-19
- Applications
- 1